Niagen Bioscience (NASDAQ:NAGE – Get Free Report) had its target price decreased by equities research analysts at Freedom Broker from $8.50 to $6.00 in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the stock. Freedom Broker‘s target price indicates a potential upside of 189.86% from the stock’s previous close.
Several other equities research analysts have also weighed in on NAGE. Roth Capital reaffirmed a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, October 15th. Finally, Canaccord Genuity Group cut their price target on shares of Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Niagen Bioscience currently has an average rating of “Buy” and an average price target of $8.50.
Check Out Our Latest Stock Report on NAGE
Niagen Bioscience Stock Performance
NAGE stock traded down $0.04 during trading on Friday, hitting $2.07. 597,674 shares of the company’s stock traded hands, compared to its average volume of 839,384. Niagen Bioscience has a 52 week low of $2.04 and a 52 week high of $7.28. The stock has a market capitalization of $164.85 million, a price-to-earnings ratio of 17.25 and a beta of 2.12. The business has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $3.85.
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $27.19 million for the quarter. Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.26%. Research analysts forecast that Niagen Bioscience will post 0.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Niagen Bioscience
Institutional investors and hedge funds have recently modified their holdings of the stock. SteelPeak Wealth LLC increased its holdings in shares of Niagen Bioscience by 2.2% during the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock valued at $10,446,000 after purchasing an additional 77,306 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after buying an additional 761,685 shares in the last quarter. Tieton Capital Management LLC purchased a new position in shares of Niagen Bioscience in the 2nd quarter valued at about $6,407,000. Renaissance Technologies LLC boosted its holdings in shares of Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after acquiring an additional 414,725 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Niagen Bioscience by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company’s stock valued at $4,723,000 after purchasing an additional 150,763 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.
Trending Headlines about Niagen Bioscience
Here are the key news stories impacting Niagen Bioscience this week:
- Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
- Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
- Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
- Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results
About Niagen Bioscience
Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.
Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.
Further Reading
- Five stocks we like better than Niagen Bioscience
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
